COPY-NUMBER SIGNATURES AND MUTATIONAL PROCESSES IN HIGH GRADE SEROUS OVARIAN CARCINOMA
Geoff Macintyre(The University of Melbourne), James D. Brenton(Cambridge University Hospitals NHS Foundation Trust), Christina Fotopoulou(Ovarian Cancer Action), Charlie Gourley(Edinburgh Cancer Research), Geoff Hall(University of Leeds), Marcia Hall(Hillingdon Hospitals NHS Foundation Trust), Luis Navarro-Sánchez, Hani Gabra(Royal Children's Hospital), Aoisha Hoyle(NHS Lanarkshire), Andrew R. Clamp, James Paul(Cancer Research UK), Axel Walther, Michelle Lockley(University College Hospital), Dilrini De Silva, Anna Supernat, Richard J. Edmondson(Manchester Academic Health Science Centre), Rosalind Glasspool(Institut Bergonié), Gareth Bryson(NHS Greater Glasgow and Clyde), Teodora Goranova(AstraZeneca (United Kingdom)), Daoud Sie(Amsterdam University Medical Centers), Sudha Sundar(Sandwell & West Birmingham Hospitals NHS Trust), Suzanne Dowson, Luiza Moore(Cambridge University Hospitals NHS Foundation Trust), Craig Nourse(Champalimaud Foundation), Oliver Hofmann(The University of Melbourne), Liz-Anne Lewsley(University of Glasgow), Florian Markowetz(Cancer Research UK), Cheryl A. Wilson(Eastern Connecticut State University), Elly Brockbank(Barts Health NHS Trust), Laura Mincarelli, Iain A. McNeish(Imperial College London), Darren Ennis, Ana Montes(Guy's and St Thomas' NHS Foundation Trust), Anna Piskorz(Cancer Research UK Cambridge Center), Matthew Eldridge(University of Cambridge), Aishah Hanif(University of Glasgow), Mercedes Jimenez‐Liñan(University of Kansas), David Millan, Bauke Ylstra(Amsterdam University Medical Centers)
Pure Amsterdam UMC
November 1, 2019
Cited by 0
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Whole–genome characterization of chemoresistant ovarian cancer
|Nature|2015|1.7k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k